Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis

Patidar, Kavish R.; Thacker, Leroy R.; Wade, James B.; White, Melanie B.; Gavis, Edith; Fagan, Andrew; Sterling, Richard K.; Fuchs, Michael; Siddiqui, Mohammad Shadab; Stravitz, R. Todd; Sanyal, Arun J.; Puri, Puneet; Luketic, Velimir A.; Bajaj, Jasmohan S.

doi:10.1007/s10620-017-4509-y

Cited by 14 publications

(12 citation statements)

References 44 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with a history of HE are at increased risk for HE recurrence; one study estimated that risk of recurrence increased by 23% with every unit increase in the number of prior overt HE episodes (hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.19–1.29) [ 12 ]. It is not uncommon for patients with overt HE to require hospitalization to manage the condition [ 13 – 15 ]; indeed, in a prospective study of patients with cirrhosis, overt HE was the most common cause of patients’ initial liver disease-related hospitalizations [ 15 ]. Further, HE was predictive of cirrhosis-related rehospitalization (odds ratio (OR) 5.5; 95% CI 2.0–15.3; p = 0.001) [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Neff

Zachry²

2018

PharmacoEconomics

View full text Add to dashboard Cite

BackgroundHepatic encephalopathy (HE), a common neurologic complication in cirrhosis, is associated with substantial disease and economic burden. Rifaximin is a non-systemic antibiotic that reduces the risk of overt HE recurrence and overt HE-related hospitalizations.ObjectiveOur objective was to provide an overview of the direct HE-related costs and cost benefits of rifaximin, lactulose, and rifaximin plus lactulose.MethodsA systematic review of PubMed and relevant meeting abstracts was conducted to identify publications since 1 January 2007 reporting economic data related to HE and rifaximin and/or lactulose. Further, a public database and published literature were used to estimate current costs of hospitalization for overt HE, and potential cost savings of HE-related hospitalizations with rifaximin. The methodological quality of included studies was evaluated using the Drummond checklist.ResultsA total of 16 reports were identified for inclusion in the systematic review. Globally, HE-related direct costs ranged from $US5370 to $US50,120 annually per patient. Rifaximin was associated with shorter hospital stays and reduced healthcare costs. Rifaximin also has the potential to reduce overt HE-related hospitalization risk by 50% compared with lactulose. Rifaximin was shown to have a favourable pharmacoeconomic profile compared with lactulose (based on the incremental cost-effectiveness ratio).ConclusionsIn addition to its clinical benefits (e.g. reduction in the risk of recurrence of overt HE, overt HE-related hospitalizations, favourable adverse event profile), economic data are favourable for the use of rifaximin in patients with a history of overt HE.

show abstract

Section: Introductionmentioning

confidence: 99%

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Neff

Zachry²

2018

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…The ultimate aim should be to embed quality of life assessment within routine practice in transplantation, which would be in line with the drive towards more patient-centred healthcare in the NHS [44,45]. Moreover, this could provide valuable clinical information given there is evidence to suggest that quality of life can be predictive of survival [46,47] and hospitalisation [48] in pre-transplantation patients.…”

Section: Discussionmentioning

confidence: 99%

The effect of liver transplantation on patient-centred outcomes: A propensity-score matched analysis

McLean

Drake

Sgrò

et al. 2020

HPB

View full text Add to dashboard Cite

Absolute standardised mean difference (aSMD), average treatment effect (ATE), average treatment effect on the control (ATC), average treatment effect on the treated (ATT), body mass index (BMI), donation after brain death (DBD), donation after circulatory death (DCD), hepatocellular carcinoma (HCC), health-related quality of life (HR-QoL), Model of End Stage Liver Disease (MELD), propensity-score matching (PSM), Short form of liver disease quality of life (SF-LDQOL). 10. Conflict of interest statement: None.

show abstract

“…HRQOL changes are important in predicting clinically relevant outcomes such as HE recurrence, hospitalizations, and death in outpatients with cirrhosis [9, 10]. Therefore, patient-reported outcomes pertaining to HRQOL should be considered integral to the prognostication and decision-making process.…”

Section: Effect Of Hepatic Encephalopathy (He) On Health-related Qualmentioning

confidence: 99%

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues

Montagnese

Bajaj

2019

Drugs

Self Cite

View full text Add to dashboard Cite

Hepatic encephalopathy (HE) has a major impact on health-related quality of life (HRQOL) in patients, which has clinical and psychosocial consequences. HRQOL in cirrhosis has been measured by generic and liver-specific instruments, with most studies indicating a negative impact of HE. HRQOL abnormalities span daily functioning, sleep–wake cycle changes, and the ability to work. Of these, sleep–wake cycle changes have a major effect on HRQOL, which remains challenging to treat. The personal effect of HRQOL is modulated by the presence of HE, the etiology of cirrhosis, and cognitive reserve. Patients with higher cognitive reserve are able to tolerate HE and its impact on HRQOL better than those with a poor cognitive reserve. The impact of HRQOL impairment is felt by patients (higher mortality and poor daily functioning), as well as by caregivers and families. Caregivers of patients with HE bear a major financial and psychological burden, which may affect their personal health and longevity.

show abstract

Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis

Abstract: Daily function and pain HRQOL domain groups using PROMIS tools independently predict hospitalizations and re-hospitalizations in cirrhotic patients.

Cited by 14 publications

References 44 publications

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

The effect of liver transplantation on patient-centred outcomes: A propensity-score matched analysis

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues

Contact Info

Product

Resources

About